Little recent data are available about the patterns of prescription for fibrates in patients
followed in primary care practices. Therefore, the goal of this study was to analyze the�…

BACKGROUND:: Clinical trials have indicated that the use of fibric acid derivatives confers a
benefit against cardiovascular disease (CVD) in selected populations. However, whether�…

Background Several clinical trials have reported inconsistent findings for the effect of fibrates
on cardiovascular risk. We undertook a systematic review and meta-analysis to investigate�…

OBJECTIVE: Fibrates might represent a viable treatment option for patients who do not meet
their target low-density lipoprotein levels on statins or who are resistant or intolerant to�…

According to recently published data, fibrates may reduce the risk of major cardiovascular
events. Whether patients with low high-density lipoprotein cholesterol (HDL-C), high�…

Introduction: The need to reduce residual cardiovascular risk led to the development of
novel therapeutic strategies to improve patients' outcomes. The residual risk in people with�…

Therapy with both statins and fibrates reduces the risk of coronary events. In the fibrate
studies the extent of reduction is disproportionately large in people with features of the�…

THE NEW ZEALAND MEDICAL JOURNAL Page 1 THE NEW ZEALAND MEDICAL JOURNAL
Vol 120 No 1261 ISSN 1175 8716 NZMJ 7 September 2007, Vol 120 No 1261 Page 1 of 4�…

The use of fibrates in the management of lipoprotein disorders has a history dating back to
the mid-1960s. This group of drugs has now been tested in several large long-term trials�…

Recent epidemiological data have reaffirmed that elevated plasma triglyceride and low HDL-
cholesterol levels are important risk factors for atherosclerotic vascular disease. The�…